The New Ruthenium(Ii)-Bipyridyl Complex with O,O '-Diethyl-(S,S)Ethylenediamine-N,N '-Di-2-(3-Cyclohexyl)Propanoate: Synthesis and Characterization by Savić, Aleksandar et al.
 
 
Macedonian Journal of Chemistry and Chemical Engineering, Vol. 33, No. 1, pp. 59–64 (2014) 
MJCCA9 – 637    ISSN 1857-5552 
Received: October 17, 2013 UDC: 546.96-386 
Accepted: January 8, 2014 Original scientific paper 
 
 
 
 
 
THE NEW RUTHENIUM(II)-BIPYRIDYL COMPLEX WITH O,O'-DIETHYL-(S,S)-
ETHYLENEDIAMINE-N,N'-DI-2-(3-CYCLOHEXYL)PROPANOATE:  
SYNTHESIS AND CHARACTERIZATION 
 
 
Aleksandar Savić1, Afya A. Baroud1, Sanja Grgurić-Šipka1* 
 
1
Faculty of Chemistry, University of Belgrade, Studentski trg 12-16, 11000 Belgrade, Serbia 
sanjag@chem.bg.ac.rs 
 
The new bipyridyl complex of ruthenium(II) with O,O'-diethyl-(S,S)-ethylenediamine-N,N'-di-2-
(3-cyclohexyl)propanoate was synthesized. The reaction of cis-[RuCl2(bpy)2] and its ligand was per-
formed in water/ethanol solution, in the presence of lithium hydroxide, under reflux. After the addition of 
ammonium hexafluorophosphate, the complex was precipitated. The complex, cis-[Ru(bpy)2L](PF6)2, was 
characterized by 1H and 13C NMR, UV-Vis, IR spectroscopy, ESI-MS spectrometry and elemental analy-
sis. Results indicate an octahedral geometry of the complex, with N,N'-coordinated O,O'-diethyl-(S,S)-
ethylenediamine-N,N'-di-2-(3-cyclohexyl)propanoate. Complexes of this type are particularly important 
in terms of potential cytotoxicity and application in photodynamic therapy. Using this therapy, many side 
effects can be reduced, which may allow the administration of higher drug dosages. 
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НОВ КОМПЛЕКС НА РУТЕНИУМ(II)-БИПИРИДИЛ СО O,O'-ДИЕТИЛ-(S,S)- 
ЕТИЛЕНДИАМИН-N,N'-ДИ-2-(3-ЦИКЛОХЕКСИЛ)ПРОПАНОАТ:  
СИНТЕЗА И КАРАКТЕРИЗАЦИЈА 
 
Синтетизиран е нов комплекс на рутениум(II) со O,O'-диетил-(S,S)-етилендиамин-N,N'-ди-2-
(3-циклохексил)пропаноат. Реакцијата на cis-[RuCl2(bpy)2] и лигандот е изведена при рефлук-
сирање на раствор вода/етанол во присуство на литиумхидроксид. Комплексот се таложи по 
додавање на амониумхексафлуорофосфат. Комплексот, cis-[Ru(bpy)2L](PF6)2, е карактеризиран по 
пат на 1H и 13C NMR, UV-Vis, IR-спектроскопија, ESI-MS-спектрометрија и елементарна анализа. 
Резултатите укажуваат дека комплексот има октагонална геометрија со N,N'-координиран O,O'-
diethyl-(S,S)-етилендиамин-N,N'-ди-2-(3-циклохексил)пропаноат. Комплексите од овој тип се осо-
бено важни во смисла на нивната потенцијална цитотоксичност и примена за фотодинамична тера-
пија. Со примена на оваа терапија се намалуваат многу споредни ефекти, што овозможува давање 
на повисоки дози на лекот. 
 
Клучни зборови: комплекси на рутениум(II); лиганд од типот на edda; фотодинамична терапија 
 
 
1. INTRODUCTION 
 
Bioinorganic chemistry is a field of inor-
ganic chemistry which is constantly evolving, par-
ticularly in recent decades, as a growing number of 
synthesized compounds are widely used for medi-
cal and pharmaceutical purposes
 
[1]. Since Rosen-
berg's discovery of cisplatin, thousands of plati-
num complexes have been synthesized, in order to 
find a more suitable anti-tumour drug. Only a 
small number has entered clinical trials and only 
two other compounds, carboplatin and oxaliplatin, 
are currently used worldwide for the treatment of 
cancer. These three compounds are used in the treat-
ment of approximately 50% of all cancer cases [2]. 
The use of these compounds is restricted be-
cause of severe dose-limiting side effects; nausea, 
vomiting, nephrotoxicity, neurotoxicity, myelo-
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suppression, and ototoxicity are frequently ob-
served [3]. To overcome these problems, the de-
velopment of novel chemotherapeutics with a dif-
ferent activity profile and mode of action, with 
lower toxicity and higher selectivity, is essential 
for the improved treatment of cancer. As a conse-
quence, complexes with other metal ions have be-
come an area of intensive research. The cytotoxic 
potential of ruthenium complexes was found three 
decades ago and the utilisation of ruthenium offers 
several advantages over platinum-based chemo-
therapy [4, 5]. Ruthenium has the ability to mimic 
iron in binding to biomolecules, which leads to 
lower toxic side effects and a different mode of 
action. Many ruthenium-based drugs are now 
promising anti-tumour agents, showing lower tox-
icity in vitro and high activity in in vivo models. 
Some of them, KP1019 and NAMI-A (Figure 1), 
have passed clinical trials and given promising re-
sults. The complexes have demonstrated lower 
general toxicity and activity towards platinum-
based drug-resistant tumours [6]. 
 
 
 
 
Fig. 1. Ru(III) complexes in clinical trials; NAMI-A and KP1019  
 
 
It is known that Ru(II) readily binds to 
ligands containing sulphur and nitrogen donor at-
oms. In recent years, the Ru(II) bi- and polypyridyl 
complexes have been a major focus, as a result of 
their good photochemical properties and their ex-
hibited anticancer activity [7, 8]. 
During the last two decades, large studies 
have focused on the field of photodynamic therapy 
(PDT), in which cancer cells are treated with 
photo-activatable drugs [9]. In this way, side ef-
fects can be reduced, which may allow the admini-
stration of higher dosages of drugs. The principle 
of PDT involves the administration of the photo-
active agent followed by local illumination of the 
tumour with light of appropriate wavelength to 
activate the specific drug. Upon illumination, the 
PDT agent is excited from its ground state to a 
singlet excited state, from where it may decay di-
rectly back to the ground state, or undergo inter-
system crossing (isc) to its long-lived triplet excited 
state
 
[10, 11] (Figure 2). The long-lived triplet excited 
state of the PDT agent sensitises the production of 
singlet oxygen (
1
O2) or produce other reactive oxy-
gen species (ROS), both of which can damage bio-
molecules
 
[12]. 
 
 
Fig. 2. Photosensitization pathways of a PDT agent 
 
 
Complexes of rhodium [13, 14] and ruthe-
nium
 
[15–17] have been extensively studied as 
agents for PDT. Some of them showed much better 
activity than cisplatin [18]. A special group of ru-
thenium complexes are compounds of the formula 
[Ru(bpy)2(L-L)]
2+
, with L-L representing the che-
lating N,N-ligand.
 
Since Chaberek and Martell first 
described the chelating ability of ethylendiamine-
N,N'-diacetic acid (H2edda), it has been of interest 
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for investigation of the mode of coordination of 
this type of ligand to various metal ions
 
[19]. This 
class acts toward different compounds including 
the esters of (S,S)-ethylenediamine-N,N'-di-2-(3-
cyclohexyl)propanoic acid. The biological activity 
of these ligands was investigated towards different 
cancer cell lines. The results obtained indicate the 
remarkable anticancer activity of these compounds
 
[20], which is comparable to cisplatin, or in the 
case of ethyl ester, even better than cisplatin.  
In this paper, we report on the synthesis and 
characterization of ruthenium(II)-bipyridyl com-
plex with O,O'-diethyl-(S,S)-ethylenediamine-N,N'-
di-2-(3-cyclohexyl)propanoate. This ligand is bi-
dentate and neutral, with an aliphatic cyclohexyl 
substituent. Due to the bulky ligand and its con-
formation, it was hypothesized that the synthesized 
complex has octahedral, cis-geometry (Figure 3). 
The coordination mode of the ligand was proposed 
on the basis of UV-Vis, IR, 
1
H, 
13
C NMR spectros-
copy, and ESI-MS spectrometry, compared with the 
already described analogous complexes and ligands. 
 
 
 
 
Fig. 3. The proposed structure of the synthesized complex 
 
 
2. EXPERIMENTAL 
 
2.1. Materials and methods  
 
(S)-2-amino-3-cyclohexyl-propanoic acid hy-
drochloride was purchased from Senn Chemicals 
(Dielsdorf, Switzerland). O,O'-diethyl-(S,S)-ethylene-
diamine-N,N'-di-2-(3-cyclohexyl)propanoate
 
[20] and 
cis-[RuCl2(bpy)2]
 
[21] were obtained as described. 
Solvents were obtained commercially and used with-
out further purification. 
Elemental analyses were carried out with the 
Elemental Vario EL III microanalyzer. Infrared 
spectra were recorded on a Nicolet 6700 FT–IR 
spectrometer using the ATR technique. The NMR 
spectra were recorded on a Varian Gemini 200 
spectrometer. Chemical shifts for 
1
H and 
13
C spec-
tra were referenced to residual 
1
H and 
13
C pre-
sented in deuterated dimethylsulphoxide. Mass 
spectra were carried out with a 6210 Time-of-
Flight LC-MS instrument (G1969A, Agilent Tech-
nologies) in acetonitrile. An electronic spectrum 
was carried out on a GBC UV–Visible Cintra 6 
spectrometer, in acetonitrile, 110–4 mol dm–3 solu-
tion of complex. Melting point was determined on 
Electrothermal melting point apparatus. 
 
2.2. Synthesis of ligand dihydrochloride, L·2HCl 
 
O,O'-diethyl-(S,S)-ethylenediamine-N,N'-di-
2-(3-cyclohexyl)propanoate dihydrochloride was 
synthesized by following an already described pro-
cedure
 
[20]. Thionyl chloride, 2.00 ml (2.70 mmol) 
and (S,S)-ethylenediamine-N,N’-di-2-(3-cyclohex-
yl)propanoic acid dihydrochloride, 1.20 g (2.70 
mmol) were added to 15 ml ice cooled absolute 
EtOH. After stirring for 1 h at 0 °C, the suspension 
was held at reflux for 16 h. The resulting mixture 
was filtered and left to crystallise. The product was 
filtered, washed with EtOH and air-dried. Com-
pound L·2HCl is a white powder, 0.56 g, (41.42 
%); m.p: 208 °C; 1H NMR (200 MHz, DMSO-d6) 
δ/ppm: 0.89 (m, C7, 4H), 1.26 (m, C5, C6, 8H; 
CH3CH2OOC–, 6 H), 1.72 (m, –CH2Cy; C4, 2H; C5, 
4H; C6, 4 H), 3.96 (s, CH3CH2OOC–, 4H), 4.05 (m, 
–NH2CH2CH2NH2–, 4 H), 4.25 (m, –OOCCHNH2–, 2H), 
10.09 ppm (m, –NH2CH2CH2NH2–, 4 H); 
13
C NMR 
(50 MHz, DMSO-d6,) δ/ppm: 14.1 CH3CH2OOC–
), 25.6 (C7), 25.6 (C4), 31.8 (C6), 33.4 (C5), 36.9 
(C3), 57.3 (C8), 62.3 (C2; CH3CH2OOC–), 169.3 
ppm (C1); IR (ATR, cm
–1
): 2900–2500, 1739, 
1450, 1215, 802; MS (LC–MS, 4000 V) m/z: 425 
([M-2HCl+H]
+
, 45.01%). Calcd. mass fractions of 
elements, w/%, for C24H46O4N2Cl2·0.5 H2O (Mr = 
497.54) are: C 56.90, H 9.35, N 5.53; found: C 56.40, 
H 8.92, N 5.50. 
 
2.3. Synthesis of starting complex,  
cis-[RuCl2(bpy)2] 
 
The synthesis was performed according to a 
slightly modified method of Sullivan
 
[21]. 
RuCl3·xH2O 1.30 g (5 mmol), 2,2
'–bipyridine 1.56 
g (10 mmol) and LiCl 2.1 g (50 mmol) were added 
in 12.5 ml DMF and refluxed for 8 h with stirring. 
Afterwards, the solution was cooled to room tem-
perature and 100 ml of a mixture of acetone/water 
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(1:1) was added. A green-black solid was separated 
by filtration. The solid was added into 100 ml wa-
ter and stirred for 10 h at r.t., followed by filtration. 
The product was then washed three times with 12.5 
ml of water and ether. The yield was 80% based on 
the ruthenium salt; 
1
H NMR (200 MHz, DMSO-d6) 
δ/ppm: 7.15 (s, C2', 2H), 7.34 (m, C1', 2H), 7.60 
(m, C3', 2H), 7.71 (s, C2, 2H), 8.06 (t, C3, 2H), 
8.51 (d, C4', 2H), 8.62 (d, C4, 2H), 9.82 ppm (s, 
C2, 2H); 
13
C NMR (50 MHz, DMSO-d6,) δ/ppm: 
122.78 (C4 and C4'), 125.55 (C2 and C2'), 134.76 
(C3 and C3'), 153.04 (C1 and C1'), 160.91 ppm 
(C5 and C5'); IR (ATR, cm
–1
): 3491.4, 3098.9, 
3068.5, 3037.6, 1604.4, 1450.4, 1417.3, 1261.4, 
1014.3, 762.0. Calcd. mass fractions of elements, 
w/%, for C20H16N4Cl2Ru·1.5 H2O (Mr = 511.37) 
are: C 47.72, H 3.80, N 11.13; found: C 47.89, H 
3.59, N 11.13. 
 
2.4. Synthesis of ruthenium(II) complex,  
cis-[Ru(bpy)2L](PF6)2 
 
cis-[RuCl2(bpy)2]∙1.5 H2O 0.10 g (0.20 
mmol) was dissolved in 10 ml mixture of etha-
nol/water (1:1), with heating at 80°C. Suspension 
of the ligand O,O'-diethyl-(S,S)-ethylenediamine-
N,N'-di-2-(3-cyclohexyl)propanoate dihydrochlori-
de 0.10 g (0.20 mmol) in ethanol (10 ml) was neu-
tralized with 1.66∙10–2 g (0.4 mmol) of LiOH∙H2O. 
During 1 h, the ligand was dropped slowly, and the 
reaction mixture was left for 4 h under reflux. Af-
ter reaction, solution was concentrated in vacuo to 
10 ml and 0.06 g solid NH4PF6 (0.37 mmol) was 
added. The mixture was stirred at r.t. for 1 h. The 
formed precipitate was filtered off and washed 
with 5.0 ml ether, and left in a desiccator to dry. 
cis-[Ru(bpy)2L]: 63.32 %; dec. temp. 182ºC; 
UV-Vis (CH3CN) λmax/nm: 380 and 471 
(ε/dm3mol–1cm−1: 7386.76 and 4845.59); 1H NMR 
(200 MHz, DMSO-d6) δ/ppm: 0.87 (t, 
CH3CH2OOC–, 6H), 0.90–1.38 (m, C10, 4H; C11, 
4H; C12, 4H; –CH2Cy, 4H; C9, 2H), 1.38–1.96 
(m, C10, 4H; C11, 4H; –NHCH2CH2NH–, 4H), 
2.09 and 2.92 (m, –OOCCHNH2, 2H), 4.19 (m, 
CH3CH2OOC–, 4H), 7.18 (m, C2 and C2', 4H), 
7.91 (m, C1 and C1', 4H), 8.25 (m, C3 and C3', 
4H), 8.60 (m, C4 and C4', 4H), 8.87 and 9.84 ppm 
(d,  –NHCH2CH2NH–, 2H); 
13
C NMR (50 MHz, 
DMSO-d6, δ/ppm) 13.48 and 14.08 (CH3CH2O-
OC–), 25.88 (C11 and C12), 33.38 (C9 and C10), 
34.90 (–CH2Cy), 57.12 (–NHCH2CH2NH–), 59.75 
(–OOCCHNH2–), 61.40 (CH3CH2OOC–), 123.93 
(C4 and C4'), 127.59 (C2 and C2'), 137.28 (C3 and 
C3'), 151.10 and 152.79 (C1 and C1'), 157.43 and 
158.36 (C5 and C5'), 171.52 ppm (CH3CH2OOC–); 
IR (ATR, cm
–1
): 3420.7, 2927.1, 2852.4, 1735.6, 
1634.2, 1604.1, 1447.8, 1268.9, 1024.5, 842.4, 
767.8, 734.8; MS m/2z: 419.18 (M
2+
, 100%) and 
983.33 ([MPF6]
+
). Calcd. mass fractions of ele-
ments, w/%, for C44H60O4N6P2F12Ru (Mr = 
1127.98) are: C 46.85; H 5.36; N 7.45; found: C 
46.54; H 5.26; N 7.18. 
 
 
 
 
Scheme: Synthesis of the complex  
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3. RESULTS AND DISCUSSION 
 
Complex cis-[Ru(bpy)2L](PF6)2 was synthe-
sized by the reaction of cis-[RuCl2(bpy)2] and 
L·2HCl in the presence of two equivalents of the 
base, LiOH, in a mixture of ethanol/water solution 
(Scheme). The desired compounds were precipi-
tated after the addition of ammonium hexafluoro-
phosphate from the reaction mixture. The com-
pound is soluble in acetonitrile and partially solu-
ble in dimethylsulphoxide, but not in water, etha-
nol or chloroform.  
 
3.1. Spectroscopic characterization 
 
The IR spectrum of the free ligand (L·2HCl) 
was compared with the corresponding spectrum of 
ruthenium(II) complex, cis-[Ru(bpy)2L](PF6)2 to 
confirm supposed coordination to the metal ion. In 
the infrared spectrum of the complex, a band 
around 3420 cm
–1
, which is typical for NH vibra-
tions of secondary amines, was observed. In the 
region 2927–2852 cm-1, strong and weak bands 
correspond to CH/CH2 vibrations of the cyclohexyl 
group and aliphatic chains. A lack of valence vi-
brations in the region 2586–2213 cm-1, which cor-
responds to valence vibrations of secondary am-
monium salt in the free ligand, indicates the coor-
dination via nitrogen donor atoms of the ester 
ligand. Strong bands corresponding to valence 
C=O vibrations are in the same position as in the 
spectrum of the ligand, suggesting that the ligand 
is not coordinated via oxygen. Other bands are at 
approximately the same position as in the spectrum 
of the ligand. The 
1
H NMR spectrum of complex 
showed characteristic bands from the 2,2'-bipyri-
dine ligand in the region 7–10 ppm. Also, NH pro-
tons from ligand are, in this region and the sum of 
the integral absorption corresponds to the number 
of protons from 2,2'-bipyridine ligand and two NH 
protons from ester. Protons from ethylene part of 
ring of complex and protons from –CHNH– group 
are moved to lower value of shifts, as a conse-
quence of the coordination of the ligand to metal. 
In the complex, the symmetry of ligand environ-
ment is lowered. In the spectrum of complex this is 
manifested by the non-equivalence of the chemi-
cally equivalent protons in free ligands, –(ROOC)-
CHNHCH2CH2NHCH(COOR)–. Signals in the 
range of 0.87–1.96 ppm correspond to cyclohexyl 
protons, protons from alkyl group (CH3CH2OOC–) 
and protons from –CH2Cy and ethylene moiety of 
ligand. Based on the interpretation of the 
13
C NMR 
spectra of the starting complex, free ligand and 
synthesized complex, it is clear that only carbons 
of the ethylene part of the ring in the complex are 
significantly moved (in the free ligand these are at 
41.81 ppm, but in the complex are at 57.12 ppm). 
Since these carbons are directly bonded for nitro-
gen atoms, these shifted signals are the result of 
coordination of the ligand to metal. The signal for 
the carbonyl group is at 171.52 ppm. Signals at 
158.36, 157.43, 152.79, 151.10, 137.29, 127.59 
and 123.93 ppm correspond to carbon atoms from 
2,2'-bipyridine ligands and these signals show 
similar shifts in the starting complex. The signal at 
61.40 ppm corresponds to carbons from ester parts, 
which are directly bonded to oxygen, and signals at 
14.08 and 13.48 ppm correspond to terminal car-
bons from the ester part. Signals at 25.86 and 33.38 
ppm are from carbons from the cyclohexyl group, 
and the signal at 59.75 ppm is attributed to carbon 
from the –OOCCHNH2– part of the ligand. Since, 
the complex cation ion, cis-[Ru(bpy)2L]
2+ 
(molecu-
lar mass: 838.36), is twice positively charged, the 
molecular ion was detected at a value of m/2e = 
419.18. The ion ([MPF6]
+
) was also detected at 
983.33.  
The synthesized complex has two peaks, at 
380 and 471 nm, which correspond to the d-d tran-
sition. The appearance of two peaks in the elec-
tronic spectrum of d
6
 system is typical for octahe-
dral geometry. This transition is in the range of 
transition bands for the d
6
 system and 
l
A1g ground 
state for octahedral geometry of ruthenium(II) 
complexes
 
[22]. Octahedral complexes demon-
strate less intensive absorptions then complexes 
with tetrahedral geometries. Since ∆t is smaller 
than ∆o, the d-d transition in the octahedral com-
plex occurs at a higher energy, and hence at a 
shorter wavelength. 
The assumption that this complex has octa-
hedral geometry is supported by its electronic 
spectrum (Figure 4). 
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Fig. 4. Electronic spectrum of the synthesized complex 
 
Efforts to obtain crystals suitable for X-ray 
analysis included: evaporation of solvent (acetoni-
trile or DMSO or acetonitrile/DMSO) at room 
temperature, cooling a saturated solution of the 
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complex in acetonitrile or acetonitrile/DMSO and 
by solvent diffusion, where we used: water, etha-
nol, or chloroform as an anti-solvent. None of 
these methods gave the crystals of desired quality. 
 
 
4. CONCLUSION 
 
The complex cis-[Ru(bpy)2L](PF6)2, where 
the L is O,O'-diethyl-(S,S)-ethylenediamine-N,N'-
di-2-(3-cyclohexyl)propanoate, has been character-
ized by means of 
1
H
 
and 
13
C NMR, elemental 
analysis, ESI-MS, IR and UV-Vis spectroscopy. 
This complex precipitates as a red powder, which 
is soluble only in acetonitrile and dimethylsulphox-
ide. The bidentate ligand is coordinated in the cis 
position, yielding the complex of octahedral ge-
ometry. This was confirmed on the basis of the IR, 
UV-Vis, 
1
H NMR, 
13
C NMR spectroscopy and 
ESI-MS spectrometry. The aims of our further 
work are the investigation of cytotoxicity and the 
possibility that this complex is used as a PDT 
agent. 
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